# Blood

Source: https://onco.cc/journals/blood/  
OnCo record `blood` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Blood is the American Society of Hematology's flagship journal, covering leukaemia, lymphoma, myeloma and transplant biology and trials, plus the ASH annual meeting abstracts.

## Summary

Blood appears weekly and publishes the science and phase 2 trials of blood cancers (venetoclax, CAR-T, bispecifics, MRD methods), the ASH abstract supplement each November, and 'How I Treat' expert reviews that shape practice. Hybrid access; articles free after 12 months. Sister titles are Blood Advances (open access) and Blood Neoplasia.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: Blood (ASH); src-blood
- Publisher: American Society of Hematology
- Scope: haematology
- Access: hybrid

## Notes

- Holds: Flagship of haematology: leukaemia, lymphoma and myeloma trials and biology; ASH abstracts. Access: Paywalled; abstracts free.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Blood_(journal)
- ASH annual meeting: https://www.hematology.org/meetings/annual-meeting

## Connected records

- collections: [ASH Annual Meeting](https://onco.cc/collections/src-ash-annual/)
- key papers: [2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party](https://onco.cc/key-papers/paper-heuser-blood/), [A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403](https://onco.cc/key-papers/paper-stock-blood/), [A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study](https://onco.cc/key-papers/paper-tam-blood/), [A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group](https://onco.cc/key-papers/paper-wattel-blood/), [ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies](https://onco.cc/key-papers/paper-zammarchi-blood/), [AZA-AML-001: azacitidine versus conventional care in older patients with acute myeloid leukaemia and more than 30 percent blasts](https://onco.cc/key-papers/paper-aza-aml-001-dombret-blood-2015/), [Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study](https://onco.cc/key-papers/paper-rockstar-blood-2021/), [Biology and treatment of Richter syndrome](https://onco.cc/key-papers/paper-rossi-richter-syndrome-blood-2018/), [BMT CTN 0803/AMC 071: autologous haematopoietic cell transplantation for HIV-related lymphoma](https://onco.cc/key-papers/paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016/), [CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia](https://onco.cc/key-papers/paper-cd19-all-leukemia-blood-2015/), [Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray](https://onco.cc/key-papers/paper-hans-immunohistochemistry-cell-of-origin-dlbcl-blood-2004/), [Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease](https://onco.cc/key-papers/paper-rosai-dorfman-destombes-consensus-recommendations-blood-2018/), [Development and validation of a predictive model for chemotherapy-associated thrombosis](https://onco.cc/key-papers/paper-khorana-blood/), [ELN 2022: diagnosis and management of acute myeloid leukaemia in adults](https://onco.cc/key-papers/paper-eln-2022-aml-dohner-blood-2022/), [Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukaemia](https://onco.cc/key-papers/paper-enasidenib-idh2-stein-blood-2017/), [Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial](https://onco.cc/key-papers/paper-epcoritamab-dlbcl-blood-2025/), [Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis and treatment in the molecular era](https://onco.cc/key-papers/paper-erdheim-chester-disease-consensus-recommendations-blood-2020/), [European LeukemiaNet recommendations for the management of acute promyelocytic leukaemia (2019 update)](https://onco.cc/key-papers/paper-eln-apl-sanz-blood-2019/), [How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies](https://onco.cc/key-papers/paper-cd19-multiple-myeloma-blood-2020/), [Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial](https://onco.cc/key-papers/paper-study-0201-blood-2006/), [Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis](https://onco.cc/key-papers/paper-raajit-rampal-blood-2014/), [Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma](https://onco.cc/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018/), [International Consensus Classification of myeloid neoplasms and acute leukaemias (2022)](https://onco.cc/key-papers/paper-icc-2022-arber-blood-2022/), [LCH-III: therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis](https://onco.cc/key-papers/paper-lch-iii-therapy-prolongation-multisystem-lch-blood-2013/), [Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-viardot-blood/), [Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure](https://onco.cc/key-papers/paper-defibrotide-2005-01-blood-2016/), [Recurrent BRAF mutations in Langerhans cell histiocytosis](https://onco.cc/key-papers/paper-badalian-very-braf-mutations-lch-blood-2010/), [Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages](https://onco.cc/key-papers/paper-emile-revised-classification-of-histiocytoses-blood-2016/), [Revisions to the staging and classification of mycosis fungoides and Sezary syndrome (ISCL/EORTC)](https://onco.cc/key-papers/paper-olsen-mycosis-fungoides-staging-blood-2007/), [Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma](https://onco.cc/key-papers/paper-sparano-blood/), [Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia](https://onco.cc/key-papers/paper-treon-blood/), [The microenvironment in mature B-cell malignancies: a target for new treatment strategies](https://onco.cc/key-papers/paper-jan-burger-blood-2009/), [Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib](https://onco.cc/key-papers/paper-jan-burger-blood-2015/)
- people: [Alex F. Herrera](https://onco.cc/people/alex-herrera/), [Andrew H. Wei](https://onco.cc/people/andrew-wei/), [C. Ola Landgren](https://onco.cc/people/ola-landgren/), [Cheryl L. Willman](https://onco.cc/people/cheryl-willman/), [Christiane Pott](https://onco.cc/people/christiane-pott/), [Claire Harrison](https://onco.cc/people/claire-harrison/), [Eytan M. Stein](https://onco.cc/people/eytan-stein/), [Jeffrey Miller](https://onco.cc/people/jeffrey-miller/), [Tao Cheng](https://onco.cc/people/tao-cheng/), [Thomas P. Loughran Jr.](https://onco.cc/people/thomas-loughran/)
- journals: [Blood Advances](https://onco.cc/journals/blood-advances/)
- institutions: [American Society of Hematology](https://onco.cc/institutions/ash/)

---
JSON: https://onco.cc/api/v1/entities/blood.json